Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.66 |
| ▸ | TLR2 | O60603 | 2/20 | 0.66 |
| ▸ | MAOA | P21397 | 5/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204448 | 1.00 | TLR4 (0.66) | TLR4TLR2MAOAMAOBPARP15 | |
| SCHEMBL31220908 | 1.00 | TLR4 (0.66) | TLR4TLR2MAOAMAOBPARP15 | |
| SCHEMBL2207924 | 1.00 | TLR4 (0.66) | TLR4TLR2MAOAMAOBPARP15 | |
| SCHEMBL2204347 | 0.98 | TLR4 (0.64) | TLR4TLR2MAOAMAOBPARP15 | |
| SCHEMBL4569068 | 0.97 | TLR4 (0.61) | TLR4TLR2MAOAMAOBPARP15 | |
| SCHEMBL510470 | 0.92 | TLR4 (0.63) | TLR4TLR2MAOAMAOBPARP15 | |
| SCHEMBL16180466 | 0.88 | TLR4 (0.53) | TLR4TLR2MAOAMAOBPARP15 | |
| SCHEMBL2151164 | 0.85 | TLR4 (0.50) | TLR4TLR2MAOAMAOBPARP15 | |
| SCHEMBL2195449 | 0.85 | TLR4 (0.53) | TLR4TLR2MAOAMAOB | |
| SCHEMBL2151045 | 0.85 | TLR4 (0.50) | TLR4TLR2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240122876-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | NATIONAL SCIENCE FOUNDATION | 2024-04-18 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022165427-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010048332-A2 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885MAOA 421/4885 |
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | TLR4 1532/4885TLR2 2711/4885MAOA 1578/4885 |
| US-20240122876-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | UACA, CRYZ, MAPT | TLR4 3374/4885TLR2 4029/4885MAOA 437/4885 |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885MAOA 421/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TLR4 517/4885TLR2 890/4885MAOA 443/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885MAOA 421/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885MAOA 421/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885MAOA 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.